These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 24195605)

  • 1. Biosafety considerations using gamma-retroviral vectors in gene therapy.
    Deichmann A; Schmidt M
    Curr Gene Ther; 2013 Dec; 13(6):469-77. PubMed ID: 24195605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosafety of recombinant adeno-associated virus vectors.
    Dismuke DJ; Tenenbaum L; Samulski RJ
    Curr Gene Ther; 2013 Dec; 13(6):434-52. PubMed ID: 24195602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Gene therapy using retrovirus vectors: vector development and biosafety at clinical trials].
    Doi K; Takeuchi Y
    Uirusu; 2015; 65(1):27-36. PubMed ID: 26923955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosafety challenges for use of lentiviral vectors in gene therapy.
    Rothe M; Modlich U; Schambach A
    Curr Gene Ther; 2013 Dec; 13(6):453-68. PubMed ID: 24195603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosafety of onco-retroviral vectors.
    VandenDriessche T; Collen D; Chuah MK
    Curr Gene Ther; 2003 Dec; 3(6):501-15. PubMed ID: 14683449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. General considerations on the biosafety of virus-derived vectors used in gene therapy and vaccination.
    Baldo A; van den Akker E; Bergmans HE; Lim F; Pauwels K
    Curr Gene Ther; 2013 Dec; 13(6):385-94. PubMed ID: 24195604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Safety of retroviral vectors in gene therapy].
    Bogoslovskaia EV; Glazkova DV; Shipulin GA; Pokrovskiĭ VV
    Vestn Ross Akad Med Nauk; 2012; (10):55-61. PubMed ID: 23240501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrovirus-induced oncogenesis and safety of retroviral vectors.
    Nair V
    Curr Opin Mol Ther; 2008 Oct; 10(5):431-8. PubMed ID: 18830918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosafety of viral vectors commonly used in gene therapy and vaccination.
    Herman P
    Curr Gene Ther; 2013 Dec; 13(6):383-4. PubMed ID: 24397526
    [No Abstract]   [Full Text] [Related]  

  • 10. Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy.
    Corrigan-Curay J; Cohen-Haguenauer O; O'Reilly M; Ross SR; Fan H; Rosenberg N; Somia N; King N; Friedmann T; Dunbar C; Aiuti A; Naldini L; Baum C; von Kalle C; Kiem HP; Montini E; Bushman F; Sorrentino BP; Carrondo M; Malech H; Gahrton G; Shapiro R; Wolff L; Rosenthal E; Jambou R; Zaia J; Kohn DB
    Mol Ther; 2012 Jun; 20(6):1084-94. PubMed ID: 22652996
    [No Abstract]   [Full Text] [Related]  

  • 11. In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors.
    Bauer G; Dao MA; Case SS; Meyerrose T; Wirthlin L; Zhou P; Wang X; Herrbrich P; Arevalo J; Csik S; Skelton DC; Walker J; Pepper K; Kohn DB; Nolta JA
    Mol Ther; 2008 Jul; 16(7):1308-15. PubMed ID: 18461052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retroviral gene therapy: safety issues and possible solutions.
    Yi Y; Hahm SH; Lee KH
    Curr Gene Ther; 2005 Feb; 5(1):25-35. PubMed ID: 15638709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Environmental risk assessment of clinical trials involving modified vaccinia virus Ankara (MVA)-based vectors.
    Goossens M; Pauwels K; Willemarck N; Breyer D
    Curr Gene Ther; 2013 Dec; 13(6):413-20. PubMed ID: 24397528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety concerns related to hematopoietic stem cell gene transfer using retroviral vectors.
    Haviernik P; Bunting KD
    Curr Gene Ther; 2004 Sep; 4(3):263-76. PubMed ID: 15384940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retroviruses as vectors.
    Vile RG; Russell SJ
    Br Med Bull; 1995 Jan; 51(1):12-30. PubMed ID: 7767638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of retroviral vectors as safe, targeted gene delivery systems.
    Günzburg WH; Salmons B
    J Mol Med (Berl); 1996 Apr; 74(4):171-82. PubMed ID: 8740648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis.
    Modlich U; Kustikova OS; Schmidt M; Rudolph C; Meyer J; Li Z; Kamino K; von Neuhoff N; Schlegelberger B; Kuehlcke K; Bunting KD; Schmidt S; Deichmann A; von Kalle C; Fehse B; Baum C
    Blood; 2005 Jun; 105(11):4235-46. PubMed ID: 15713797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retroviral vectors: post entry events and genomic alterations.
    Nowrouzi A; Glimm H; von Kalle C; Schmidt M
    Viruses; 2011 May; 3(5):429-55. PubMed ID: 21994741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production.
    Sinn PL; Sauter SL; McCray PB
    Gene Ther; 2005 Jul; 12(14):1089-98. PubMed ID: 16003340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrovirus-mediated gene transfer in cancer therapy.
    Uckert W; Walther W
    Pharmacol Ther; 1994 Sep; 63(3):323-47. PubMed ID: 7530375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.